245 FIRST STREET, CAMBRIDGE, MA
Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Stockholders Elect Adrian Adams, Michael Rogers, and LeAnne Zumwalt as Directors
Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Annual Report to Security Holders
Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
.2AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT
Investor Presentation
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Definitive Revised Proxy Statement
Confidential Treatment Order